Mediaplanet and RxSight® Team Up to Bring Awareness to Eye Health and Vision Care
ALISO VIEJO, Calif., Jan. 6, 2023 /PRNewswire-PRWeb/ -- Approximately 32 million Americans reported experiencing vision loss in 2018, and more than half of all Americans will have cataracts by age 80. Luckily, cataract surgery is effective and safe, with 90% of patients reporting improved vision. However, many people report that their post-surgery vision isn't as good as they'd hoped.
Leading medical technology company, RxSight®, joins Mediaplanet's Vision Care campaign to shed light on breakthrough technology for cataract patients
ALISO VIEJO, Calif., Jan. 6, 2023 /PRNewswire-PRWeb/ -- Approximately 32 million Americans reported experiencing vision loss in 2018, and more than half of all Americans will have cataracts by age 80. Luckily, cataract surgery is effective and safe, with 90% of patients reporting improved vision. However, many people report that their post-surgery vision isn't as good as they'd hoped.
The Light Adjustable LensTM (LAL®) by RxSight® is aiming to fix this dilemma by allowing you to test drive your post-cataract surgery vision. "What's unique about the Light Adjustable Lens is that the adjustment is done post-op," notes Dr. Dan Durrie, renowned eye surgeon and RxSight consultant. "A month after surgery, the patient has the chance to say, 'Gee, this is good, but maybe my vision needs to be a little better,' and then you have a chance to adjust it".
The Light Adjustable Lens is a game changer for anyone dealing with cataracts, or anyone concerned for their overall eye health. The ability to adjust the prescription of the lenses up to three times dramatically increases the effectiveness of surgery in improving the vision of those suffering from cataracts. In one study involving 600 participants, for example, cataract sufferers who received the LAL with the necessary adjustments were twice as likely to have achieved 20/20 distance vision without glasses.
The print component of "Vision Care" is distributed within today's edition of USA Today in New York, Los Angeles, Chicago, Atlanta, Philadelphia, Baltimore, North and Central Florida, Detroit, Cincinnati, Nashville, New Orleans, Pittsburgh, Cleveland, and Boston markets, with a circulation of approximately 150,000 copies and an estimated readership of 450,000. The digital component is distributed nationally through a vast social media strategy and across a network of top news sites and partner outlets. To explore the digital version of the campaign, visit: https://www.futureofpersonalhealth.com/campaign/vision-care/
About RxSight®:
RxSight is a commercial-stage medical technology company dedicated to improving the vision of patients following cataract surgery. RxSight's FDA-approved proprietary Light Adjustable Lens system consists of our Light Adjustable Lens (LAL®), Light Delivery Device (LDD™) and accessories. It is the first and only commercially available intraocular lens technology that enables doctors to customize and optimize visual acuity for patients after cataract surgery. With the RxSight system, doctors perform a standard cataract procedure to implant the LAL, determine refractive error with patient input after healing is complete, then use the LDD to reshape the LAL with the exact amount of visual correction needed to achieve the patients' desired vision outcomes.
Press Contact:
Anisa Nammar
[email protected]
(949) 273-6171
Media Contact
Anisa Nammar, RxSight, (949) 273-6171, [email protected]
SOURCE RxSight
